These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
277 related items for PubMed ID: 9096697
1. Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts. Reuter C, Schleyer E, Rolf C, Wörmann B, Büchner T, Hiddemann W. Leukemia; 1997 Apr; 11(4):561-71. PubMed ID: 9096697 [Abstract] [Full Text] [Related]
2. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Reuter C, Auf der Landwehr U, Schleyer E, Zühlsdorf M, Ameling C, Rolf C, Wörmann B, Büchner T, Hiddemann W. Leukemia; 1994 Feb; 8(2):217-25. PubMed ID: 8309245 [Abstract] [Full Text] [Related]
3. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia. Jahns-Streubel G, Reuter C, Unterhalt M, Schleyer E, Wörmann B, Büchner T, Hiddemann W. Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275 [Abstract] [Full Text] [Related]
4. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado AM, Jasiok M. Blood; 1991 Nov 15; 78(10):2674-9. PubMed ID: 1824260 [Abstract] [Full Text] [Related]
5. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Hiddemann W, Kiehl M, Zühlsdorf M, Busemann C, Schleyer E, Wörmann B, Büchner T. Semin Oncol; 1992 Apr 15; 19(2 Suppl 4):31-7. PubMed ID: 1553573 [Abstract] [Full Text] [Related]
8. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Jahns-Streubel G, Reuter C, Auf der Landwehr U, Unterhalt M, Schleyer E, Wörmann B, Büchner T, Hiddemann W. Blood; 1997 Sep 01; 90(5):1968-76. PubMed ID: 9292531 [Abstract] [Full Text] [Related]
9. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine. Braess J, Wegendt C, Jahns-Streubel G, Kern W, Keye S, Unterhalt M, Schleyer E, Hiddemann W. Br J Haematol; 2000 May 01; 109(2):388-95. PubMed ID: 10848830 [Abstract] [Full Text] [Related]
10. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity. Koistinen P, Wang C, Curtis JE, McCulloch EA. Leukemia; 1991 Sep 01; 5(9):789-95. PubMed ID: 1719308 [Abstract] [Full Text] [Related]
11. Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF. Jahns-Streubel G, Braess J, Schoch C, Fonatsch C, Haase D, Binder C, Wörmann B, Büchner T, Hiddemann W. Leukemia; 2001 Mar 01; 15(3):377-84. PubMed ID: 11237060 [Abstract] [Full Text] [Related]
12. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity. Braess J, Voss S, Jahns-Streubel G, Schoch C, Haferlach T, Kern W, Keye S, Schleyer E, Hiddemann W. Br J Haematol; 2000 Jul 01; 110(1):170-9. PubMed ID: 10930995 [Abstract] [Full Text] [Related]
13. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. te Boekhorst PA, Löwenberg B, Sonneveld P. Leukemia; 1994 Sep 01; 8(9):1480-6. PubMed ID: 7522289 [Abstract] [Full Text] [Related]
14. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Yang GS, Minden MD, McCulloch EA. Leukemia; 1993 Jul 01; 7(7):1012-9. PubMed ID: 7686602 [Abstract] [Full Text] [Related]
15. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors. Waga K, Furusawa S, Nagashima S, Saito K, Shishido H. Int J Hematol; 1992 Aug 01; 56(1):17-27. PubMed ID: 1391803 [Abstract] [Full Text] [Related]
18. In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity. Van der Lely N, De Witte T, Wessels J, Raymakers R, Muus P, Preijers F. Ann Hematol; 1994 May 01; 68(5):225-32. PubMed ID: 7517190 [Abstract] [Full Text] [Related]
19. Effects of rhGM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity. Karp JE, Burke PJ, Donehower RC. Leukemia; 1990 Aug 01; 4(8):553-6. PubMed ID: 2201833 [Abstract] [Full Text] [Related]
20. The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology. Wang LM, White JC, Capizzi RL. Cancer Chemother Pharmacol; 1990 Aug 01; 25(6):418-24. PubMed ID: 2311169 [Abstract] [Full Text] [Related] Page: [Next] [New Search]